PRODUCING HUMANIZED MONOCLONAL ANTIBODIES WITH TRANSGENIC MICE

Antibodies drive the human adaptive immune response, allowing for the recognition and elimination of a tremendous range of external threats. Immunotherapy has harnessed the innate properties of the antibody, converting the protein from a threat-recognition agent into a disease-fighting one. New immunotherapeutic strategies such as monoclonal antibody therapy demand new high-throughput production of selective and non-autoimmunogenic custom-engineered antibodies for both research.
Read more...

;